Doximity, Inc. (NASDAQ:DOCS) Shares Sold by Pinebridge Investments L.P.

Pinebridge Investments L.P. trimmed its holdings in Doximity, Inc. (NASDAQ:DOCS) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,382 shares of the company’s stock after selling 4,884 shares during the quarter. Pinebridge Investments L.P.’s holdings in Doximity were worth $608,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Global Retirement Partners LLC lifted its stake in Doximity by 468.1% in the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock worth $29,000 after purchasing an additional 440 shares in the last quarter. UMB Bank n.a. raised its position in shares of Doximity by 69.1% during the 4th quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after buying an additional 235 shares during the period. Larson Financial Group LLC raised its position in shares of Doximity by 49.4% during the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock valued at $40,000 after buying an additional 250 shares during the period. Optimum Investment Advisors purchased a new stake in shares of Doximity during the 4th quarter valued at approximately $43,000. Finally, Morse Asset Management Inc purchased a new stake in shares of Doximity during the 3rd quarter valued at approximately $46,000. 87.19% of the stock is owned by hedge funds and other institutional investors.

Doximity Price Performance

NASDAQ:DOCS opened at $56.75 on Tuesday. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $85.21. The firm has a market capitalization of $10.59 billion, a PE ratio of 56.75, a price-to-earnings-growth ratio of 4.10 and a beta of 1.41. The business’s fifty day moving average price is $60.30 and its 200 day moving average price is $56.37.

Insider Transactions at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 37.40% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Raymond James reaffirmed an “outperform” rating and set a $83.00 price target (up previously from $65.00) on shares of Doximity in a research report on Friday, February 7th. Mizuho lifted their price target on shares of Doximity from $55.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Needham & Company LLC lifted their price target on shares of Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 7th. The Goldman Sachs Group boosted their target price on Doximity from $58.00 to $80.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Finally, Leerink Partners raised Doximity from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $60.00 to $90.00 in a research report on Friday, February 7th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $65.39.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.